Functional Imaging of Cognitive Impairment in Parkinson's Disease

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical EEG and Neuroscience

• Publication date

  2010-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1177/155005941004100303PMID 20722344
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cognitive Impairment and Dementia in Parkinson's Disease

  2019cited by this paper
• Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains.

  2010cited by this paper
• Medication impairs probabilistic classification learning in Parkinson's disease.

  2010cited by this paper
• In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

  2010cited by this paper
• Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment

  2009cited by this paper
• Parkinson Disease With Dementia: Comparing Patients With and Without Alzheimer Pathology

  2009cited by this paper
• Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration—[18F]FDG‐PET

  2009cited by this paper
• Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease.

  2009cited by this paper
• Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease

  2009cited by this paper
• The clinical impression of severity index for Parkinson's disease: International validation study

  2009cited by this paper
• Metabolic brain networks in neurodegenerative disorders: a functional imaging approach.

  2009cited by this paper
• Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography

  2009cited by this paper
• Neural correlates of STN DBS-induced cognitive variability in Parkinson disease.

  2008cited by this paper
• [11C]PIB binding in Parkinson's disease dementia

  2008cited by this paper
• Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study.

  2008cited by this paper
• Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease

  2008cited by this paper
• Dopaminergic Suppression of Brain Deactivation Responses during Sequence Learning

  2008cited by this paper
• Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

  2008cited by this paper
• Imaging amyloid deposition in Lewy body diseases

  2008cited by this paper
• Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET

  2008cited by this paper
• PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.

  2008cited by this paper
• Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease

  2008cited by this paper
• Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging

  2008cited by this paper
• Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.

  2008cited by this paper
• Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA.

  2008cited by this paper
• Changes in Cerebral Glucose Metabolism in Patients with Parkinson Disease with Dementia After Cholinesterase Inhibitor Therapy

  2008cited by this paper
• Cognitive Impairment in Parkinson’s Disease and Dementia with Lewy Bodies: A Spectrum of Disease

  2007cited by this paper
• DLB and PDD boundary issues

  2007cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007cited by this paper
• Functional Imaging of Working Memory in Parkinson's Disease: Compensations and Deficits

  2007cited by this paper
• Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease

  2007cited by this paper
• Metabolic brain networks associated with cognitive function in Parkinson's disease

  2007cited by this paper
• Changes in network activity with the progression of Parkinson's disease.

  2007cited by this paper
• In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies

  2007cited by this paper
• Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET

  2007cited by this paper
• Abnormal Metabolic Network Activity in Parkinson'S Disease: Test—Retest Reproducibility

  2007cited by this paper
• ‘Prefrontal’ cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: An exploratory [18F]‐fluoro‐L‐DOPA‐PET investigation

  2007cited by this paper
• Imaging treatment effects in Alzheimer's disease.

  2007cited by this paper
• Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia

  2006cited by this paper
• Striatal dopamine release during performance of executive functions: A [11C] raclopride PET study

  2006cited by this paper
• In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease.

  2006cited by this paper
• Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease

  2006cited by this paper
• Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease

  2006cited by this paper
• Network modulation in the treatment of Parkinson's disease.

  2006cited by this paper
• Functional imaging of sequence learning in Parkinson's disease.

  2006cited by this paper
• Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia

  2006cited by this paper
• PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease

  2006cited by this paper
• Differences in neuropathologic characteristics across the Lewy body dementia spectrum

  2006cited by this paper
• with the cognitive function of attention in Alzheimer's disease

  2006cited by this paper
• A systematic review of prevalence studies of dementia in Parkinson's disease

  2005cited by this paper
• Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.

  2005cited by this paper
• Dementia in Parkinson disease

  2005cited by this paper
• Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.

  2005cited by this paper
• Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease

  2005cited by this paper
• Neuroimaging and therapeutics in movement disorders

  2005cited by this paper
• Neuroimaging and therapeutics in movement disorders

  2005cited by this paper
• Cognitive dysfunction and dementia in Parkinson’s disease

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

  2004cited by this paper
• Subthalamic Nucleus Stimulation Restores Glucose Metabolism in Associative and Limbic Cortices and in Cerebellum: Evidence from a FDG-PET Study in Advanced Parkinson's Disease

  2004cited by this paper
• Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies

  2004cited by this paper
• Executive processes in Parkinson's disease: FDG‐PET and network analysis

  2004cited by this paper
• Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism

  2004cited by this paper
• Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

  2003cited by this paper
• Learning networks in health and Parkinson's disease: Reproducibility and treatment effects

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

  2003cited by this paper
• α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

  2003cited by this paper
• Effects of levodopa on motor sequence learning in Parkinson’s disease

  2003cited by this paper
• A Review of the Cognitive and Behavioral Sequelae of Parkinson's Disease: Relationship to Frontostriatal Circuitry

  2003cited by this paper
• Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease

  2003cited by this paper
• Can Alzheimer’s Disease and Dementias with Lewy Bodies be Distinguished Clinically?

  2003cited by this paper
• Enhancement of brain activation during trial-and-error sequence learning in early PD

  2003cited by this paper
• Activation of basal ganglia loops in idiopathic Parkinson’s disease: a PET study

  2003cited by this paper
• Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin.

  2003cited by this paper
• Functional imaging of cognition in Parkinson's disease

  2003cited by this paper
• Nicotine and nicotinic receptors; relevance to Parkinson's disease.

  2002cited by this paper
• Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease.

  2002cited by this paper
• Cognitive impairments in advanced PD without dementia

  2002cited by this paper
• Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study.

  2002cited by this paper
• Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.

  2002cited by this paper
• Subthalamic nucleus stimulation affects striato-anterior cingulate cortex circuit in a response conflict task: a PET study.

  2002cited by this paper
• Searching for a baseline: Functional imaging and the resting human brain

  2001cited by this paper
• Functional networks in motor sequence learning: Abnormal topographies in Parkinson's disease

  2001cited by this paper
• The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease.

  2001cited by this paper
• Metabolic correlates of levodopa response in Parkinson’s disease

  2001cited by this paper
• Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.

  2000cited by this paper
• Mental symptoms in Parkinson's disease are important contributors to caregiver distress

  1999cited by this paper
• Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors

  1998cited by this paper
• Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions.

  1998cited by this paper
• Cerebral glucose metabolism in Parkinson's disease with and without dementia.

  1992cited by this paper
• Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse.

  1988cited by this paper

• Cortical Thinning and Cognitive Impairment in Parkinson's Disease without Dementia

  2018cites this paper
• In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease

  2018cites this paper
• Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study

  2015cites this paper